Licensing status

Publication and contact

Pulmonary disease

Pulmonary fibrosis

IL-25 (IL-17E)

Patient sample and mouse studies suggest inhibiting IL-25 could help treat pulmonary fibrosis. In a mouse model of Schistosoma mansoni egg-induced pulmonary fibrosis, Il-25 knockout mice had lower numbers of profibrotic, Il-13-producing type II innate lymphoid cells and lower levels of Il-13 and fibrosis than wild-type mice. In tissue samples from patients with idiopathic pulmonary fibrosis (IPF), levels of IL-25, type II innate lymphoid cells and IL-13 were greater than those in tissue samples from patients without fibrotic lesions. Next steps could include testing IL-25 depletion in additional fibrosis models and developing IL-25-specific inhibitors.
Amgen Inc., AstraZeneca plc and Kyowa Hakko Kirin Co. Ltd. have brodalumab, an IL-17 receptor (IL17R; IL17RA) antibody, in Phase III testing to treat psoriasis and psoriatic arthritis and Phase II trials to treat asthma.

SciBX 7(5); doi:10.1038/scibx.2014.150
Published online Feb. 6, 2014

Patent and licensing status undisclosed

Hams, E. et al. Proc. Natl. Acad. Sci. USA; published online Dec. 16, 2013;
Contact: Padraic G. Fallon, Trinity College Dublin, Dublin, Ireland